Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/05/20
The U.S. Department of Defense Awards $1.1 Million to CytoSorbents to Optimize Development of HemoDefend-BGA™ for Life-saving Universal PlasmaPRNewsWire • 10/09/20
CytoSorb Achieves Registration in Brazil and Is Now Commercially Available To Treat Cytokine Storm in COVID-19 Infection and Other ConditionsPRNewsWire • 09/21/20
CytoSorbents Announces the "CytoSorb Therapy in COVID-19 ICU Patients" (CTC) Registry Is Actively EnrollingPRNewsWire • 09/08/20
CytoSorbents Partners with InvoSurg and Surgical Partners to Commercialize CytoSorb® in the U.S. Northeast, Mid-Atlantic, and Florida under FDA Emergency Use Authorization for COVID-19PRNewsWire • 08/17/20
Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/05/20
CytoSorbents Achieves Milestone of More than 100,000 CytoSorb Treatments Delivered Cumulatively To DatePRNewsWire • 08/03/20
CytoSorbents Awarded $4.4 Million Contract by the U.S. Department of Defense to Complete HemoDefend-BGA Adsorber Preclinical DevelopmentPRNewsWire • 07/31/20
CytoSorbents Announces the REFRESH 2-AKI Trial Data Monitoring Committee Has Recommended Study Resumption Following Favorable Review of Safety DataPRNewsWire • 07/28/20
CytoSorbents Corporation Announces Pricing of $50 Million Public Offering of Common StockPRNewsWire • 07/22/20
CytoSorbents Provides Preliminary Q2 2020 Financial Results and Corporate UpdatePRNewsWire • 07/20/20
CytoSorbents Corporation Announces Proposed $40 Million Public Offering of Common StockPRNewsWire • 07/20/20
CytoSorbents to Host Key Opinion Leader Call on the Use of CytoSorb Blood Purification to Remove Antithrombotic Medications in Patients at Risk of BleedingPRNewsWire • 06/29/20
CytoSorbents Announces Commercial Launch and Immediate Availability of CytoSorb To Treat Cytokine Storm In Many Latin American Countries As COVID-19 Cases RisePRNewsWire • 06/24/20
CytoSorbents Awarded $2,897,172 Phase III STTR Contract to Advance HemoDefend-BGA Plasma and Whole Blood Filter to Clinical TrialsPRNewsWire • 06/09/20